Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

Abstract Introduction Outcomes after frontline treatment of Burkitt lymphoma (BL) have improved with the introduction of dose‐intense chemotherapy regimens, such as CODOX‐M/IVAC. While rituximab has increased survival rates for most forms of high‐grade B‐cell lymphoma, there has previously been hesi...

Descrición completa

Detalles Bibliográficos
Main Authors: Elizabeth H. Phillips, Catherine Burton, Amy A. Kirkwood, Sharon Barrans, Anthony Lawrie, Simon Rule, Russell Patmore, Ruth Pettengell, Kirit M. Ardeshna, Silvia Montoto, Shankara Paneesha, Laura Clifton‐Hadley, David C. Linch, Andrew K. McMillan
Formato: Artigo
Idioma:English
Publicado: Wiley 2020-07-01
Series:eJHaem
Subjects:
chemotherapy
CNS
HIV
immunotherapy
lymphomas
monoclonal antibodies
Acceso en liña:https://doi.org/10.1002/jha2.3

Internet

https://doi.org/10.1002/jha2.3

Títulos similares